DAXOR CORP

DXRNASDAQ

🏆 #3517 by market capEarnings Aug 20US Equity

$1,002.32▲ $18.84 (+1.88%)

Simulated price

1h—

24h▲ 1.9%

7d—

14d—

30d—

1y—

🏦Market Cap

$61M

Small Cap

📈Revenue Growth (YoY)

-77.7%

Declining

📊Gross Margin

-3917.2%

Thin

💵FCF Margin

2139.2%

Strong

⚖️P/S Ratio

2207.3x

Expensive

Otter Score

Weak

No chart data available for DXR.

Trading Snapshot

Day Range: $989.43 – $1,019.01
52-Week Range: $8.56 – $14.76
Volume: $3.86B
Avg Volume: $4.34B
Shares Outstanding: 5.8M
Next Earnings: Sep 25, 2026

Fundamentals Snapshot

Annual Revenue: $503,424
Last Q Revenue: $131,846
P/E Ratio: 6.4
P/S Ratio: 2207.3x
EPS (TTM): $1.98
Dividend Yield: —

Why Investors Own DXR

✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$503,424▲ +33.1% YoY

Gross Margin (TTM)

78.4%▲ +0.1% YoY

Operating Income (TTM)

$154,048▲ +33.1% YoY

Free Cash Flow (TTM)

$89,609▲ +33.1% YoY

About DAXOR CORP

Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.

🦦